Design Therapeutics, a preclinical biotech developing gene targeted chimeras for nucleotide expansion diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Design Therapeutics, a preclinical biotech developing small molecule therapies for genetic diseases, announced terms for its IPO on Monday. The Carlsbad, CA-based company plans to raise $228 million ...
NEW YORK (CBS.MW) -- Biotechnology stocks fell Friday with shares of Protein Design Labs continuing to sink in the wake of an executive shakeup. The Amex Biotechnology Index BTK slid 1.5 percent and ...
Kristofer Mussar, PhD, is COO of VectorBuilder and MD of VectorBuilder GmbH, leading global operations and innovation in gene delivery. What if business leaders approached strategy the way scientists ...
Researchers have successfully grown bacterial cells in potential sand-based construction materials, as detailed in a paper published by Research Directions: Biotechnology Design, a new journal from ...
SAN DIEGO--(BUSINESS WIRE)-- Oncolytics Biotech (ONCY) ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced alignment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback